A federal jury in San Francisco awarded Illumina $26.7 million in a lawsuit accusing Ariosa Diagnostics, now owned by Roche, of infringing on two Illumina prenatal testing patents.

The jury rejected counterclaims by Ariosa that Illumina had breached a supply agreement between the companies by bringing the lawsuit.

The US Patent and Trademark Office previously upheld the patents, striking down multiple challenges from Ariosa, according to Illumina, a genome sequencing company headquarted in San Diego.

“This verdict again validates these patents, the hard work and ingenuity of the inventors, and their significant contribution to the field of NIPT (non-invasive prenatal test),” said Charles Dadswell, senior vice president and general counsel for Illumina, in a news release.

Ariosa Diagnostics is based in San Jose.